https://scholars.lib.ntu.edu.tw/handle/123456789/637870
標題: | Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC | 作者: | Planchard, David Jänne, Pasi A Cheng, Ying CHIH-HSIN YANG Yanagitani, Noriko Kim, Sang-We Sugawara, Shunichi Yu, Yan FAN YUN Geater, Sarayut L Laktionov, Konstantin Lee, Chee K Valdiviezo, Natalia Ahmed, Samreen Maurel, Jean-Marc Andrasina, Igor Goldman, Jonathan Ghiorghiu, Dana Rukazenkov, Yuri Todd, Alex Kobayashi, Kunihiko |
公開日期: | 23-十一月-2023 | 卷: | 389 | 期: | 21 | 來源出版物: | The New England journal of medicine | 摘要: | Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/637870 | ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa2306434 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。